FDA Updates

New Product Newswire

New drugs, new indications, new generics, OTCs, health & beauty care, etc. (Includes ad index)

Clinicians can now offer their patients the first nonsystemic, gastrointestinal selective antibiotic to receive FDA approval. The agency recently approved rifaximin (Xifaxan, Salix Pharmaceuticals) tablets for the treatment of TD caused by noninvasive strains of Escherichia coli in those 12 years of age or older. Rifaximin is currently approved for use in 17 countries worldwide. It is expected to be available in U.S. pharmacies in August.

New Product Newswire

Some new products featured include the generic version of Macrobid and eye drop accessories